Health Trials

Clinical trials

6

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Safety and Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells in Preventing Arteriovenous Fistula Stenosis in Patients With End-Stage Diabetic Kidney Disease

A Study on the Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells in Preventing Arteriovenous Fistula Stenosis

Participants needed: 54
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Jiangsu Topcel-KH Pharmaceutical Co., Ltd.Updated: Mar 5, 2026
Eligibility criteria

Diabetic nephropathy with estimated glomerular filtration rate (eGFR) < 15 mL/mi... [+3]

Patients with conditions unsuitable for AVF, including surgical site infection,... [+6]

Read more
Status: Recruiting

Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma

The purpose of this study is to evaluate the safety and tolerability of BAFF-R CAR-T Cells in Adult Subjects with CD19-Negative relapsed or refractory B-Cell Lymphoma.

Participants needed: 30
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Jiangsu Topcel-KH Pharmaceutical Co., Ltd.Updated: Feb 27, 2026Locations: 1
Eligibility criteria

1. Subjects voluntarily participate in clinical research and sign informed conse... [+13]

1. Women who are pregnant or breastfeeding, or planned pregnancy within 6 months... [+7]

Read more
Status: Recruiting

Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

The purpose of this study is to investigate the safety and tolerability of anti-PD1 armored CD19 CAR-T Cells in adult subjects with relapsed or refractory diffuse large B-cell lymphoma.

Participants needed: 30
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Jiangsu Topcel-KH Pharmaceutical Co., Ltd.Updated: Jan 28, 2026Locations: 1
Eligibility criteria

1. Subjects voluntarily participate in clinical research and sign informed conse... [+14]

1. Women who are pregnant or breastfeeding, or planned pregnancy within 6 months... [+7]

Read more
Status: Recruiting

Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease

The purpose of this study is to evaluate the efficacy of human TH-SC01 cell injection for the treatment of perianal fistulas in Crohn's Disease over 24 weeks.

Participants needed: 228
Trial details
Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Jiangsu Topcel-KH Pharmaceutical Co., Ltd.Updated: Apr 13, 2025Locations: 1
Eligibility criteria

Signed informed consent [+6]

Subjects allergic to human serum albumin, human platelet lysate, gentamicin sulf... [+21]

Read more
Status: Not yet recruiting

Evaluate the Distribution and Dynamic Behavior of Nuclide Labeled TH-SC01 Cells in Vivo in Patients With Radiation Proctitis

A Phase l clinical study evaluating the distribution and dynamic behavior of Nuclide labeled TH-SC01 cells in vivo in patients with Radiation proctitis

Participants needed: 6
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Jiangsu Topcel-KH Pharmaceutical Co., Ltd.Updated: Apr 13, 2025
Eligibility criteria

Signed informed consent [+5]

Patients with severe, progressive and uncontrollable diseases of the liver, bloo... [+10]

Read more
Status: Recruiting

Umbilical-Cord-Derived Mesenchymal Stem Cells Injection for Chronic Radiation Proctitis

A Phase I/II study to evaluate the safety and preliminary efficacy of human umbilical cord-derived mesenchymal stem cell injection for the treatment of chronic radiation proctitis.

Participants needed: 24
Trial details
Phase: Phase 1, Phase 2Age: 18-79Biological sex: AllType: InterventionalSponsor: Jiangsu Topcel-KH Pharmaceutical Co., Ltd.Updated: Jun 21, 2024Locations: 1
Eligibility criteria

Fully understand and sign the informed consent form; [+6]

Patients with severe liver or kidney dysfunction during the screening period; [+9]

Read more